Charles River Laboratories International (NYSE:CRL) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Charles River Laboratories International (NYSE:CRL) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

A number of other research analysts have also commented on the stock. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their price objective for the company from $142.00 to $195.00 in a research note on Tuesday, September 9th. Evercore ISI boosted their price target on Charles River Laboratories International from $190.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, October 3rd. William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Barclays increased their price objective on Charles River Laboratories International from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $186.93.

Charles River Laboratories International Trading Down 1.7%

CRL opened at $167.99 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. Charles River Laboratories International has a 52 week low of $91.86 and a 52 week high of $222.10. The business’s 50 day moving average is $168.00 and its two-hundred day moving average is $155.35. The firm has a market cap of $8.27 billion, a price-to-earnings ratio of -126.31, a price-to-earnings-growth ratio of 4.83 and a beta of 1.53.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. During the same period last year, the firm posted $2.59 earnings per share. The company’s revenue for the quarter was down .5% compared to the same quarter last year. On average, research analysts predict that Charles River Laboratories International will post 9.36 EPS for the current year.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Institutional investors have recently made changes to their positions in the stock. Brooklyn Investment Group lifted its stake in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 86 shares during the period. Cromwell Holdings LLC lifted its position in shares of Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 152 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Charles River Laboratories International during the 2nd quarter worth approximately $29,000. Rothschild Investment LLC boosted its stake in shares of Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares in the last quarter. Finally, Atlantic Union Bankshares Corp acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter worth approximately $31,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).